Strikingly, 73% of non-tumor cases (11 out of 15) were more than 50% methylated, whereas 53% of tumor cases (8 out of 15) were less than 30% methylated at the NANOG promoter (Figure 3B and 3C). This evidence concerns the gene NANOG and neoplasm.